Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma

Key Points

• To compare treatment switching rates and therapy sequencing among zanubrutinib, acalabrutinib, and ibrutinib in CLL and SLL.
• Analyzed treatment data for zanubrutinib, acalabrutinib, and ibrutinib.
• Compared 90-day switching rates between treatments.
• Assessed proportion of patients on the next line of therapy at 180 days.
• Zanubrutinib showed lower 90-day switching rates compared to acalabrutinib and ibrutinib.
• A higher proportion of patients receiving zanubrutinib were on the next line of therapy at 180 days.